Immutep (IMMP) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Immutep Limited has reported significant progress in its clinical trials, including positive outcomes from the TACTI-003 Phase IIb trial for first-line head and neck cancer and successful dosing in the first human trial of IMP761 for autoimmune diseases. The company has been added to the S&P ASX300 Index, highlighting its growth and market visibility. Additionally, Immutep maintains a robust financial position with cash reserves of A$172.3 million, ensuring operational stability through to the end of 2026.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
